Summary
Extended-release (ER) opioid formulations are often targeted for misuse and abuse because they contain high amounts of opioid. An oral abuse-deterrent formulation of ER morphine sulfate tablets (morphine ARER [abuse-resistant extended-release], MorphaBondTM ER) resists physical manipulation and chemical extraction, forms a nonsyringeable material in liquid environments, and retains its ER characteristics despite manipulation. Morphine ARER is formulated with multiple overlapping physiochemical barriers instead of antagonists or aversive agents to deter misuse and abuse. When crushed and taken intranasally, morphine ARER has a 40% lower mean maximum drug-liking score than crushed intranasal morphine ER.
Register to download
Pharmacokinetic Charcateristic of Oral_Intranasal Morphine ARER
You may also be interested in:
resource
Opportunities in low-level radiocarbon microtracing: applications and new technology
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation,…
Poster
Select Characteristics of Recreational Opioid Users Undergoing a Human Abuse Potential Study
Human abuse potential (HAP) studies are conducted to determine the potential abuse of a drug that has rewarding properties. Abuse potential refers to…
Capability
ECG Assessments in Renal and Hepatic Impaired Patients
PRA’s dedicated early phase professionals leverage proven expertise in renal and hepatic impairment to provide clients with high quality ECG…